(Sharecast News) - Drugmaker GSK said on Thursday that regulators in Japan and China had accepted two separate new drug applications for review, covering investigational treatments targeting chronic hepatitis B and cholestatic pruritus in primary biliary cholangitis.
For hepatitis B, Japan's Ministry of Health, Labour and Welfare accepted the company's filing...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE